Premium
The effect of neoadjuvant androgen suppression on prostate cancer‐related outcomes after high‐intensity focused ultrasound therapy
Author(s) -
Uchida Toyoaki,
Illing Rowland O.,
Cathcart Paul J.,
Emberton Mark
Publication year - 2006
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2006.06369.x
Subject(s) - medicine , prostate cancer , high intensity focused ultrasound , prostate , hormonal therapy , neoadjuvant therapy , urology , oncology , cancer , ultrasound , radiology , breast cancer
OBJECTIVE To explore the effect of neoadjuvant androgen suppression (AS) compared to no AS on cancer‐related outcomes after radical high‐intensity focused ultrasound (HIFU) therapy for men with presumed organ‐confined prostate cancer. PATIENTS AND METHODS Between January 1999 and January 2005, 250 patients underwent HIFU for presumed localized adenocarcinoma of the prostate; 154 had received neoadjuvant hormonal therapy and 96 had not. The primary outcome measure was treatment failure, as defined by the presence of prostate cancer on the biopsy taken 6 months after HIFU. Multiple logistic regression was used to examine relationships between the use of HIFU with and with no neoadjuvant AS and treatment failure. RESULTS The treatment failure rate was slightly lower in patients receiving neoadjuvant AS (31% vs 34%), but this was not statistically significant ( P = 0.119). CONCLUSION In this unrandomized comparison between neoadjuvant or no AS before HIFU for men with presumed organ‐confined prostate cancer, there appeared to be little if any benefit associated with the previous administration of AS.